OncUpdates· @OncUpdates · X·· 2 days agoScore70
Body
⭐️ #ESMO26 | #HERIZON-GEA-01: OS benefit with zanidatamab regimens in 1L HER2+ mGEA
🎙️ @KlempnerSam & @ShrutiPatelMD
✅ mOS: 22.9 vs 19.6 mo (HR 0.76) zani+chemo vs tras+chemo
✅ Triplet mOS: 27 mo
#GIOnc #HER2 #OncTwitter #gism
🎥 Full discussion 👇
https://oncupdates.com/video-podcasts/ep-1-updated-herizon-gea-01-trial-results-show-survival-benefit-with-zanidatamab-based-regimens-at-esmo-2026/
24 views · 1 like · 0 reposts · 0 replies
Conference abstracts
LBA79matched by Rapid oral 1: Gastrointestinal tumour, upper digestive
Zanidatamab (zani) + chemotherapy (CT) ± tislelizumab (TIS) for first-line (1L) HER2-positive (HER2+) advanced/metastatic gastroesophageal adenocarcinoma (mGEA): Second interim analysis (IA) from HERIZON-GEA-01
https://esmocongress.esmo.orgSource: OncUpdates · x.com